Relmada Therapeutics (RLMD) News Today

Relmada Therapeutics logo
$3.01 -0.60 (-16.62%)
Closing price 04:00 PM Eastern
Extended Trading
$3.13 +0.12 (+4.12%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Why Is Relmada Therapeutics Dropping Today?

Relmada Therapeutics, Inc. (NASDAQ: RLMD) had two potentially positive developments: it appointed an experienced uro-oncology executive to lead development of its bladder-cancer candidate, and HC Wainwright raised its earnings estimates. The appointment supports preparations for a planned Phase 3 trial, but the candidate remains in development, so clinical and regulatory risks remain. The supplied news does not identify a clear negative catalyst for the stock.

  • Positive Sentiment: Relmada named Jørn Skibsted Jakobsen, who led development of the bladder-cancer therapy ADSTILADRIN through global approvals, as Chief Development Officer for Urology & Uro-Oncology. He will oversee NDV-01 development as Relmada prepares the Phase 3 SPECTRUM program. The appointment brings relevant clinical and regulatory experience, though it does not guarantee trial success. Relmada appoints uro-oncology leader as Chief Development Officer
  • Positive Sentiment: HC Wainwright revised its quarterly and annual EPS forecasts upward, generally projecting smaller losses. Its FY2027 estimate improved to a loss of $0.52 per share from $0.61, and its FY2030 outlook shifted from a loss of $0.06 to a profit of $0.01 per share. These are analyst estimates, not company guidance. HC Wainwright earnings estimate revisions
  • Neutral Sentiment: NDV-01’s Phase 2 results were described as showing durable responses and favorable tolerability, but the planned Phase 3 SPECTRUM trial and further regulatory steps remain important milestones. The news provided no new trial results or confirmed Phase 3 outcome. Relmada appoints CDO to lead NDV-01 urology program
Posted 4m agoAI Generated. May Contain Errors.

Relmada Therapeutics Latest News

RLMD Stock Gets Stronger EPS Estimate from HC Wainwright
Relmada (RLMD) Q3 2026 Earnings Call Transcript
Relmada Therapeutics Q3 Loss Narrows
RLMD Share News Today
Relmada (RLMD) Q2 2026 Earnings Call Transcript
Relmada Therapeutics Inc

Relmada Therapeutics Media Mentions By Week

Relmada Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RLMD
News Sentiment
▼
0.78

0.56
▲
Average
Healthcare
News Sentiment

Relmada Therapeutics News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RLMD Articles
This Week
▼
21

2
▲
RLMD Articles
Average Week

Relmada Therapeutics Trends on MarketBeat

This week vs. last week
New Followers
1
Searches
1
Page Views
858
-21%
Get Relmada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Relmada Therapeutics dated 11/17/2026.
From Our Partners